Avner Shemer, Nir Nathansohn, Henri Trau
Department of Dermatology, C. Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Israel.
J Dermatolog Treat. 2005;16(5-6):327-30. doi: 10.1080/09546630500420183.
Treatment of onychomycosis has recently been enhanced by the introduction of combination therapies.
To evaluate the efficacy of a combination therapy of ciclopirox nail lacquer and oral terbinafine compared to oral terbinafine monotherapy for the treatment of onychomycosis caused by dermatophytes.
Eighty patients with onychomycosis were randomly assigned to receive either oral terbinafine 250 mg/day for 16 weeks or a combination of oral terbinafine 250 mg/day for 16 weeks and topical ciclopirox nail lacquer once daily for 9 months. Both groups were followed up for 9 months from start of treatment.
After 9 months of treatment, the mycological cure rates were 22/34 (64.7%) for the terbinafine-only group and 30/34 (88.2%) for the combination therapy group (p<0.05). No significant difference was noted in the complete cure rate.
Combination therapy of oral terbinafine and ciclopirox nail lacquer is a safe and more effective treatment for onychomycosis than terbinafine alone, especially in younger patients and in shorter-duration onychomycosis.
联合疗法的引入最近增强了甲癣的治疗效果。
评估环吡酮甲涂剂与口服特比萘芬联合疗法相较于口服特比萘芬单一疗法治疗皮肤癣菌引起的甲癣的疗效。
80例甲癣患者被随机分配，分别接受口服特比萘芬250毫克/天，持续16周，或口服特比萘芬250毫克/天持续16周并联合外用环吡酮甲涂剂，每天一次，持续9个月。两组均从治疗开始随访9个月。
治疗9个月后，单一特比萘芬组的真菌学治愈率为22/34（64.7%），联合治疗组为30/34（88.2%）（p<0.05）。完全治愈率无显著差异。
口服特比萘芬与环吡酮甲涂剂联合治疗甲癣比单用特比萘芬更安全、有效，尤其对于年轻患者和病程较短的甲癣。
